Duchenne News Tags: Edgewise

September 12, 2022
On Sept. 12, 2022, Edgewise Therapeutics released positive 4-month interim data from their open label study in individuals with Becker muscular dystrophy.
September 7, 2022
On Sept. 7, 2022, Edgewise announced that the FDA has authorized its Phase 2 clinical trial for the treatment of Duchenne. They expect to begin dosing participants in the fourth quarter of 2022. 
July 14, 2022
On July 12, 2022, Edgewise Therapeutics shared a press release announcing the opening of the CANYON Phase 2 clinical trial of their investigational compound, EDG-5506, in individuals with Becker muscular dystrophy.
Edgewise Duchenne News
June 21, 2022
On June 20, 2022, Edgewise Therapeutics announced positive results from the ARCH open label study of EDG-5506.

Experience the magic of camp promise

Complete applications due April 3, 2023.